AB Biotics ABB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 26.36
- Price/Sales
- 4.73
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.03%
Company Profile
AB Biotics is is a biotech company that focuses on the research and development of a vast generation of natural probiotic strains formulated not only to meet therapeutic needs but also to maintain human health.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 34
- Website
- https://www.ab-biotics.com
Comparables
Valuation
Metric
|
ABB
|
016580
|
FAE
|
---|---|---|---|
Price/Earnings (Normalized) | 26.36 | 7.11 | 8.97 |
Price/Book Value | 7.94 | 0.59 | 1.54 |
Price/Sales | 4.73 | 0.92 | 2.34 |
Price/Cash Flow | 19.62 | 5.43 | 8.96 |
Price/Earnings
ABB
016580
FAE
Financial Strength
Metric
|
ABB
|
016580
|
FAE
|
---|---|---|---|
Quick Ratio | 1.81 | 3.93 | 1.85 |
Current Ratio | 2.07 | 5.30 | 3.34 |
Interest Coverage | 9.55 | 1,345.19 | 266.72 |
Quick Ratio
ABB
016580
FAE
Profitability
Metric
|
ABB
|
016580
|
FAE
|
---|---|---|---|
Return on Assets (Normalized) | 15.87% | 7.92% | 12.46% |
Return on Equity (Normalized) | 34.85% | 8.87% | 14.75% |
Return on Invested Capital (Normalized) | 30.61% | 7.89% | 14.15% |
Return on Assets
ABB
016580
FAE
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bfdswgtq | Tzz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pbfjyzx | Dhgdyy | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tkrpwsj | Ptvmzl | $97.8 Bil | |
MRNA
| Moderna Inc | Mhlzsdbmz | Vsggb | $38.8 Bil | |
ARGX
| argenx SE ADR | Vwszqhdnw | Wpmw | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Pdjlynn | Wzsb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nkptplwz | Vbjct | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jkgjdppkd | Zvnjlx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ykrmdqgryj | Dnpndtc | $12.5 Bil | |
INCY
| Incyte Corp | Hbbfmgpb | Ytqzqfx | $11.5 Bil |